CANCER CHEMOTHERAPY ASSOCIATED NAUSEA AND VOMITING THERAPEUTICS MARKET ANALYSIS

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type (Acute CINV, Delayed CINV, Anticipatory nausea and emesis and Breakthrough CINV/Refractory CINV), By Drug Class (Dopamine Receptor Antagonists (Metoclopramide, Chlorpromazine, Prochlorperazine, Haloperidol, Droperidol and Others), Serotonin (5-HT3) receptor Antagonists (Ondansetron, Granisetron, Palonosetron, Dolasetron and others), Substance P/NK-1 Antagonists (Aprepitant, Fosaprepitant, Netupitant, and Others), Corticosteroids (Dexamethasone and Methylprednisolone) and others), By Route of Administration (Oral, Parenteral and Transdermal Patch), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI5823
Pages :266
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market growth can be hindered by high cost of chemotherapy-induced nausea and vomiting (cinv) treatment drugs. For instance, according to GoodRx, Inc., a healthcare company that operates a telemedicine platform and a free-to-use website and mobile app that track prescription drug prices in the U.S., the average retail price of 1 capsule Akynzeo (Netupitant and Palonosetron Capsules) is around US$ 570.8.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market : Restraint

Poor Reimbursement Policies

Poor reimbursement policies and healthcare financing structures in low economies such as Middle East is expected to act as a restraint for the market growth over the forecast period. For instance, according to an article published by the European Medical Journal, in August 2020, antiemetic guidelines are valid in countries where drugs are available and reimbursed; however, this is not the case in some parts of the world.